A Phase 4 interventional study of Ticagrelor and Clopidogrel in Acute Coronary Syndrome, sponsored by AstraZeneca. Completed at 16 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2015-12-11.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 24th largest by enrollment, is one of 7 that started in 2012, is one of 38 in phase 4, and was the 5th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18+
Shanghai Tong Ren Hospital · Sites in China
Ages 75+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 38
First in 2006; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 120 across the 67 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2012, is one of 5 in phase 4, and was the 14th registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ticagrelor - 180 mg loading dose
Drug: Ticagrelor
Clopidogrel - 600 mg loading dose
Drug: Clopidogrel
180 mg loading dose
600 mg loading dose
Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™
Participants with low (\<150) baseline PRU values were excluded.
Time frame: 2 hours after the loading dose
Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™
Participants with low (\<150) baseline PRU values were excluded.
Time frame: 0.5 hours, end of PCI, and 8 hours after the loading dose
Participants recruited from 15 actively participating sites in the United States of America, from July 2012 until June 2014.
| Milestone | Ticagrelor | Clopidogrel |
|---|---|---|
| Started | 51 | 49 |
| Completed | 49 | 48 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Failed inclusion criterion after dosed | 1 | 0 |
Participants with low (\<150) baseline PRU values were excluded.
| PRU | Ticagrelor | Clopidogrel |
|---|---|---|
| Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ | 98.4 ± 95.4 | 257.5 ± 74.5 |
Participants with low (\<150) baseline PRU values were excluded.
| PRU | Ticagrelor | Clopidogrel |
|---|---|---|
| 0.5 hours | 277.3 ± 73.8 | 297.7 ± 69.2 |
| 8 hours | 43.8 ± 45.7 | 202.3 ± 89.1 |
| End of PCI (n=41 for ticagrelor) | 264.2 ± 92.2 | 307.8 ± 59.5 |
Collected over All adverse events (AEs), including serious AEs were monitored from the point of informed consent through the 14 day follow up period. All vascular events were assessed at each visit and could be reported by participants at any time during the study.. Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor | — | 9/51 (17.6%) | 5/51 (9.8%) |
| Clopidogrel | — | 5/49 (10.2%) | 1/49 (2%) |
| Event | Ticagrelor | Clopidogrel |
|---|---|---|
| Angina unstableCardiac disorders | 0/51 | 3/49 |
| Chest painGeneral disorders | 2/51 | 1/49 |
| HypotensionVascular disorders | 2/51 | 0/49 |
| PneumoniaInfections and infestations | 0/51 | 1/49 |
| Coronary artery diseaseCardiac disorders | 0/51 | 1/49 |
| FallInjury, poisoning and procedural complications | 0/51 | 1/49 |
| DuodenitisGastrointestinal disorders | 1/51 | 0/49 |
| Lactic acidosisMetabolism and nutrition disorders | 1/51 | 0/49 |
| Grand mal convulsionNervous system disorders | 1/51 | 0/49 |
| Partial seizuresNervous system disorders | 1/51 | 0/49 |
| Event | Ticagrelor | Clopidogrel |
|---|---|---|
| Chest painGeneral disorders | 2/51 | 0/49 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/51 | 1/49 |
| HaematomaVascular disorders | 2/51 | 0/49 |
Randomized Analysis Set, defined as all participants who signed informed consent, who provided demographic and/or baseline screening assessments, and who were randomized into the study regardless of the participant's randomization and treatment status in the study.
| Age, Categorical(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 36 | 30 | 66 |
| >=65 years | 15 | 19 | 34 |
| Sex: Female, Male(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| Female | 17 | 13 | 30 |
| Male | 34 | 36 | 70 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 2 | 3 |
| Black or African American | 11 | 11 | 22 |
| White | 33 | 33 | 66 |
| Missing values | 5 | 3 | 8 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 11 | 14 | 25 |
| Not Reported | 28 | 27 | 55 |
| Missing values | 7 | 7 | 14 |
| Region of Enrollment(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| United States | 51 | 49 | 100 |
The record gives a start of Jul 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor